ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP16

Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis

Ashley Krivohlavek, Oklahoma City, OK

Meeting: ACR Convergence 2022

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Perspectives Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I’m now 38.

In 2020, I had been on an infused biologic for 18 months, but my dose was wearing off between infusions. My disease activity was worsening, and my CRP kept going up. My rheumatologist recommended an injectable. I started the new medication in spring; by summer I was miserable. I had pain, swelling, fatigue, and brain fog. This meant I was unable to do basic activities like laundry, cooking, or even walking.

At the end of August, I asked my provider for a new medication. I was met with no sense of collaboration. She said there was no reason for my worsening symptoms and that it may be fibromyalgia. I left that appointment feeling dismayed by the lack of collaboration and hopeless at the prospect of managing an added diagnosis.

Intervention: I started researching. I Googled medical studies and articles about PsA with fibromyalgia and medications. I discovered that PsA and fibromyalgia are comorbidities and that switching biologics can cause flares. What I was experiencing aligned with symptoms of uncontrolled PsA with a few overlapping fibromyalgia symptoms.

I also looked for other rheumatologists. I consulted with the Dean of Rheumatology at my state university who confirmed that I was not a candidate for fibromyalgia. My symptoms were likely due to uncontrolled PsA. She gave me the name of another rheumatologist, who also confirmed the same.

In a rheumatology desert, with few options, I thought I might have to travel out of state. Fortunately, I stumbled on a practice new to my area that employed nurse practitioners with rheumatology specialization and made an appointment. The first thing my new provider said was that she expected me to be a collaborator in my health journey. I was the captain of my ship, and she was there to support me. She read my notes prior to our visit and ordered extensive labs. We scheduled a follow-up to review my labs and discuss next steps. I felt understood and hopeful.

Maintenance: Since 2021, my health has improved. Gone is the constant fatigue and brain fog and aching swollen joints. My CRP levels are lower than they’ve been since my PsA diagnosis.

Quality of Life: My life has become my own again. I re-started graduate school and have been volunteering in health advocacy in my state. The time and effort that goes into having a chronic illness has also become less burdensome: I don’t need to travel to doctor’s appointments as often and I spend less time on the phone with my doctor’s office and insurance company.

This has all been possible because of the collaborative relationship I now have with my rheumatology provider. I communicate with my provider about my needs and PsA goals and she listens and provides constructive feedback. To maintain our collaborative relationship, I wrote up patient communication principles based on my experience (Table 1). If I need to change my provider again in the future, I know I can do so with confidence using my Guide to Changing Providers (Figure 1).

Supporting image 1

Table 1. Guide to Collaborating with Your Provider

Supporting image 2

Figure 1. Guide to Changing Providers


Disclosures: A. Krivohlavek, None.

To cite this abstract in AMA style:

Krivohlavek A. Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/please-hear-me-how-effective-provider-patient-communication-improved-my-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/please-hear-me-how-effective-provider-patient-communication-improved-my-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology